MK5172-017. Phase II Long Term Safety Mrs Sherryl 13/CEN/182 Approve Observational Follow up Hayett Transfer from Methadone to Dr David 13/CEN/183 Approve Intervention Buprenorphine Newcombe 13/CEN/185 Approve The ASCOLT Study Dr Mark Jeffery Intervention A study of PF-04950615 versus placebo 13/CEN/186 Provisionally approve for the reduction of cardiovascular events Dr John Baker Intervention (B1481022) A Study Comparing GDC-0199 and Rituximab to Bendamustine and Rituximab Dr Andrew 13/CEN/187 Provisionally approve Intervention in Patients with Relapsed/Refractory Butler Chronic Lymphocytic Leukaemia. Associate 13/CEN/20 Approve CLDK378A2203 Professor Mark ADHB Intervention McKeage Dr Douglas 13/CEN/24 Approve Maxigesic 325 OA Study Intervention White Tivantinib vs Placebo for the treatment of Auckland District Health 13/CEN/25 Approve Prof Ed Gane Intervention Inoperable Hepatocellular Carcinoma Board Dr Mark 13/CEN/26 Approve Clinical Study ADHB Intervention Webster A clinical for children with low and Dr Robin Paul 13/CEN/27 Approve CDHB Research Office Intervention intermediate risk Neuroblastoma Corbett Dr D 13/CEN/28 Approve Integration and Tinnitus Intervention Searchfield Diagnosis of Coeliac disease in New Dr Jonathan Auckland District Health 13/CEN/3 Approve Observational Zealand children Bishop Board Assoc. 13/CEN/30 Approve Mothers and Babies Bodies. Professor Jane Observational Coad Acetazolamide to reduce lithium induced Professor 13/CEN/31 Decline Intervention NDI Robert Walker
13/CEN/182 Approve MK5172-017. Phase II Long Term Safety Follow up Mrs Sherryl Hayett Observational 13/CEN/183 Approve Transfer from Methadone to Buprenorphine Dr David Newcombe Intervention 13/CEN/185 Approve The ASCOLT Study Dr Mark Jeffery Intervention 13/CEN/186 Provisionally approve A study of PF-04950615 versus placebo for the reduction of cardiovascular events (B1481022) Dr John Baker Intervention 13/CEN/187 Provisionally approve A Study Comparing GDC-0199 and Rituximab to Bendamustine and Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukaemia. Dr Andrew Butler Intervention 13/CEN/20 Approve CLDK378A2203 Associate Professor Mark McKeage ADHB Intervention 13/CEN/24 Approve Maxigesic 325 OA Study Dr Douglas White Intervention 13/CEN/25 Approve Tivantinib vs Placebo for the treatment of Inoperable Hepatocellular Carcinoma Prof Ed Gane Auckland District Health Board Intervention 13/CEN/26 Approve Clinical Study Dr Mark Webster ADHB Intervention 13/CEN/27 Approve A clinical for children with low and intermediate risk Neuroblastoma Dr Robin Paul Corbett CDHB Research Office Intervention 13/CEN/28 Approve Integration and Tinnitus Dr D Searchfield Intervention 13/CEN/3 Approve Diagnosis of Coeliac disease in New Zealand children Dr Jonathan Bishop Auckland District Health Board Observational 13/CEN/30 Approve Mothers and Babies Bodies. Assoc. Professor Jane Coad Observational 13/CEN/31 Decline Acetazolamide to reduce lithium induced NDI Professor Robert Walker Intervention
central-regional-ethics-committee-annual-report-2013.docx